Mavacamten: Novel Therapeutic Agent for Obstructive Hypertrophic Cardiomyopathy (HCM)

Mavacamten is a new allosteric inhibitor of cardiac myosin ATPase, designed to reduce sarcomere hypercontractility, a key mechanism in obstructive hypertrophic cardiomyopathy. By decreasing actin-myosin cross-bridge interactions, Mavacamten helps to attenuate contractility, relieve left ventricular outflow tract (LVOT) obstruction, and improve myocardial energetics. Trials for long-term safety and efficacy are ongoing, but this promising agent marks a significant advancement in managing obstructive HCM.

Caveats:

• Not studied in patients with LVEF <55%, atrial fibrillation, or those with prior invasive septal reduction.
• Excludes pregnant and lactating patients, so safety in these populations remains unknown.
• Long-term safety and efficacy data are still forthcoming.

Produced by: Dr. Kate Wilcox
Reviewed by: Dr. Ahmed Ghoneem

CardioNerds Infographics

Explore our comprehensive collection of infographics, categorized by cardiovascular topics such as heart failure and transplantation, arrhythmias and electrophysiology, cardio-obstetrics, cardiovascular imaging, congenital heart disease, prevention, coronary artery disease, critical care, hypertension, pericardial disease, pulmonary hypertension, valvular heart disease, vascular disease, women’s cardiovascular health, diversity, inclusion, and more!

Feel free to download and share these visuals in presentations or on social media. Please use the infographics as provided—without altering or cropping out the creators’ credit.

For even more learning, explore the CardioNerds Tweetorial Page, featuring a curated collection of educational tweetorials!